Desirability and feasibility of a vaccine against cytomegalovirus. - Wikidata - wikimedia - TriplyDB

Desirability and feasibility of a vaccine against cytomegalovirus.

Desirability and feasibility of a vaccine against cytomegalovirus.

http://www.wikidata.org/entity/Q38100041

about

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.Prevention of Primary Cytomegalovirus Infection in Pregnancy.Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX Inhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense.Human cytomegalovirus tropism for mucosal myeloid dendritic cells.Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies Reduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infection Complete protection of mice against lethal murine cytomegalovirus challenge by immunization with DNA vaccines encoding envelope glycoprotein complex III antigens gH, gL and gO Novel heparan sulfate-binding peptides for blocking herpesvirus entry.A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection.Limits and patterns of cytomegalovirus genomic diversity in humans.Genetic identification of cytomegaloviruses in a rural population of Côte d'Ivoire.Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?Awareness of Cytomegalovirus Infection among Pregnant Women in Geneva, Switzerland: A Cross-sectional Study.Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection aga Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity Cytomegalovirus in the neonate: immune correlates of infection and protection Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts.Vaccination against a virus-encoded cytokine significantly restricts viral challenge Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?Molecular and biological characterization of a new isolate of guinea pig cytomegalovirus.Quantification of cytomegalovirus viral load.Cytomegalovirus infection in liver transplant recipients: updates on clinical management Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Treatment of perinatal viral infections to improve neurologic outcomes.Increasing Complexity of Vaccine Development.Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus.The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.APOBEC3A is Upregulated by Human Cytomegalovirus in the Maternal-Fetal Interface, Acting as an Innate Anti-HCMV Effector.Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence Programming CMV for vaccine vector design.A Bioreactor Method to Generate High-titer, Genetically Stable, Clinical-isolate Human Cytomegalovirus.

P2860

Q21089588-0F4186BC-9EA3-4ED9-B365-AB5C77628874 Q27692570-A53192F8-0073-41CD-B362-FDA9FF6F85C9 Q30666266-2BD77226-3D64-441F-92EB-9696E6F4C2CC Q33744024-9D0958CB-D6F4-4D04-9E10-A433CEDD3773 Q34047484-2C89D34B-B899-4E07-BD90-830E1ED38560 Q34422068-199BB2C7-D447-4C6F-B20F-D35C9DC42C39 Q34753135-73C4CB48-2C20-4796-9E72-08DE8A52DA0C Q35196400-04D224AF-A75B-4FB6-BB88-9D0FF4373F4C Q35214272-F8C8C2BD-3ED5-43B9-ACA8-9EC282D7448A Q35636214-50F5B8E9-B12F-4851-960B-5B0E6706B6D4 Q35886919-166B7C60-C031-4E95-912F-D6FCAD8ACD43 Q35910248-FF5E56E8-E9C9-4CC8-94DC-D0C0038AF8C3 Q36126229-3CF2B109-0C1A-486D-A7E0-DB331C1E233C Q36210368-03BE185C-26BB-43FB-BA19-7E55BCEA2DE2 Q36281094-B4C8D942-1B59-4F91-A55E-68FF46A93679 Q36302615-4B72F9E9-D7C2-4504-9483-CB78CE8EAF82 Q36403590-B65CF3A2-2D41-4D59-8205-8578AE5CBAC2 Q36430938-2D83C100-08B9-421A-9E3C-C9468D30CFBF Q36633558-E3EBCA1A-4CF6-446A-9239-3257069A811C Q36830632-38B59B33-5D27-4CAF-AE9D-E28CA5C392AE Q36977623-2AB239FD-35C4-4185-B26D-F57E8D60C053 Q37140130-3782CBAA-E020-4E77-9F0A-92ADAA360EAB Q37222032-B477E556-7B1F-4A29-B07A-E01ABD07F44D Q37252720-340FB721-1280-4E1E-B07A-5AB1E5C5B6AA Q37409233-C8B8A308-8B02-4465-BAFC-89DC44EAED98 Q37574334-9E6E4475-126A-4962-9192-EB4201CF210D Q37611802-1294DF0E-B269-40C2-9991-F29418083BD0 Q38171537-E0F6117E-540B-4C3A-B4B5-620EAECC7E3B Q38242802-73DA189D-7D9F-480F-8323-C21BA3F9FCC1 Q38797660-6DCE06D5-7663-4A0C-ACA0-FA287D574C4B Q38802522-5C155E4E-1D17-4A07-A18D-95FBEE0EB8C2 Q38875887-C7D4A068-4B2E-48F8-BFD0-44FB69170AF7 Q38965659-D3D8C7AF-2625-403F-ACC3-3A66A912D302 Q38990899-14D557EB-5699-4A5F-98FD-F053F24E1C48 Q40375876-B52514D9-E04A-4DAF-942E-74A50C215442 Q40483485-16A59431-C0FE-4AA5-A588-B3EA8D00F54C Q41928866-54835456-FCF2-4336-BA3A-C2EAF352D049 Q41929983-014A37EE-3896-440B-9BFC-3BB5F6F4B6CE Q42270816-FD5B6820-F0CA-4D4A-9155-B244A0931A43 Q46065213-227CDB99-5E19-4D36-8071-502195F7723F

P2860

Desirability and feasibility of a vaccine against cytomegalovirus.

http://www.wikidata.org/entity/Q38100041

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Desirability and feasibility of a vaccine against cytomegalovirus.

@en

type

label

Desirability and feasibility of a vaccine against cytomegalovirus.

@en

prefLabel

Desirability and feasibility of a vaccine against cytomegalovirus.

@en

P1433

Q38100041-DBB8D961-2B6C-40FC-AFA4-EEE50101CD45

P1476

Q38100041-7651A582-57C6-4A9A-994F-EB1041067272

P2093

Q38100041-6587BFDE-E45B-4B50-BB6A-C347A68B8C91

Q38100041-A4323324-48BB-45C6-A270-C38F8F7174DB

Q38100041-ABA1444B-1F0E-42C0-B835-08842149BFCA

Q38100041-AD943525-BECF-42C1-9E6F-FD73DC7A2886

Q38100041-F86558EA-BE8B-441D-A021-820D98E215F5

P2860

Q38100041-060F6FC6-3193-461E-9EC7-DDBB6E0F59CC

Q38100041-06E80022-A41B-4576-BF73-63C97772EF85

Q38100041-0C752805-167A-418A-9AAE-AD25EDCFCF97

Q38100041-11554015-6D20-4864-9304-510F506185C4

Q38100041-15AAFD37-A1C6-462B-B779-68F4477711E9

Q38100041-17B9B0F1-8854-4A2B-9BFB-3C9FFB154270

Q38100041-20826BC3-D99E-4D67-B27A-8DC003CACA38

Q38100041-22B067EA-2DC7-450D-BC34-B42C6899EB21

Q38100041-252E7BBF-8044-4CF5-A85B-C26AFC6A4BC6

Q38100041-2845E9D1-EB42-4797-8067-D240E3989849

P304

Q38100041-3E2E1699-3EDF-49D3-AD79-36112A7D8DD1

P31

Q38100041-44652C1F-380D-4A4F-962C-8AEF558BE498

P356

Q38100041-0B1E4022-3630-4EF7-8289-C9D61C7DCDF2

P407

Q38100041-7505D1BB-F5C0-4C21-82F5-79CC2091470A

P478

Q38100041-8D9A993E-0425-4163-AD6F-502CE5A5B332

P50

Q38100041-5DA352FB-8F88-4D92-9454-8377EA49C413

Q38100041-98E1077F-2090-4EA7-8D67-59A0BD01EEA1

P577

Q38100041-4CF4154D-B965-47C6-BDD2-A794A305E046

P5875

Q38100041-C0E7E2C2-B9BB-4841-A504-0A4FC0759CA3

P698

Q38100041-5FCFEF13-43F1-40BF-B951-1B35616638F9

P921

Q38100041-96D65C59-8F12-47EC-A901-31E49A1E31DD

P932

Q38100041-DFF0D60C-DADE-4863-B555-29FCADFEA26F

P356

J.VACCINE.2012.10.074

P1433

P1476

Desirability and feasibility of a vaccine against cytomegalovirus.

@en

P2093

Edward Mocarski

http://www.w3.org/2001/XMLSchema#string

Mark Schleiss

http://www.w3.org/2001/XMLSchema#string

Paul Griffiths

http://www.w3.org/2001/XMLSchema#string

Robert Pass

http://www.w3.org/2001/XMLSchema#string

Stephanie Bialek

http://www.w3.org/2001/XMLSchema#string

P2860

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

Vaccine prevention of maternal cytomegalovirus infection

Washing our hands of the congenital cytomegalovirus disease epidemic.

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

Cytomegalovirus infection in the normal host

Incidence of cytomegalovirus infection among the general population and pregnant women in the United States.

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States.

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.

Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection

P304

B197-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2012.10.074

http://www.w3.org/2001/XMLSchema#string

P407

P478

31 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P50

Philip R Krause

Stanley Plotkin

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257098146

http://www.w3.org/2001/XMLSchema#string

P698

23598482

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

P932

5672921

http://www.w3.org/2001/XMLSchema#string